Michael Mullan Alzheimers Research

 

The Roskamp Institute is devoted to understanding causes of and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. Based in Sarasota, Florida, the Institute utilizes a broad range of scientific approaches to understanding the causes of and potential therapies for these disorders with an emphasis on Alzheimer’s disease.

Headed by Dr. Michael Mullan, the institute employs experienced and interdisciplinary scientists and technicians and houses state-of-the-art research labs and equipment to conduct scientific research. The quality of research performed at the institute reflects its motto: “Better science. Real discovery.”

 

Michael Mullan is a biomedical researcher of the β-amyloid protein and its relation to Alzheimer’s disease. Mullan’s Alzheimer research is well known among Biomedical Community. Dr. Mullan Alzheimer research work resulted in identifying the most widely known Swiss Mutation that is present in familial form. Transgenic Animal for Alzheimer Disease uses Swiss Mutation.

Dr. Mullan is currently the director[1] of the Roskamp Institute in Sarasota, Florida. Under Dr. Mullan’s guidelines the institute is carrying out cutting edge research in Alzheimer’s, Traumatic Brain Research, Gulf War Illness and other neuropsychiatric disorder.

 

Please visit websites to learn about Dr. Mullan Alzheimer’s Research Website:

 

 

Recent Posts

Michael Mullan: Brain Fitness Programs – a scam ?

Perform a web search on “brain scam” and you will find several articles questioning the veracity of claims made with respect to brain fitness or brain exercise programs. Are these programs a scam? One thing is clear, they appear to be rapidly increasing in popularity – all the way from self help books and DVDs to computer based brain fitness games. In the first category, Dr. Daniel Amen’s program is probably one of the most well known and in the second category, the Lumosity program is gaining widespread recognition. In both cases there are websites addressing the question of whether these programs are associated with scams. But are they? The answer depends on what the expectations are from such programs. This article will address one potential expectation that many may have – namely that such programs will prevent Alzheimer’s disease.

Is using the brain in brain fitness programs a way to prevent Alzheimer’s? The scientific facts are that engaging the brain in intellectual tasks throughout life is “protective” against Alzheimer’s, but even this statement needs to be carefully evaluated. What is actually meant by this is that individuals who have higher levels of education tend to have Alzheimer’s disease later in life if at all, and so seem relatively protected against it. Many studies have shown that more intensive and longer duration of education are associated with reduced age matched rates of Alzheimer’s. In addition, the type of occupation one has, which commonly reflects the degree of brain effort required, also correlates with rates of onset of Alzheimer’s at specific ages. So the idea of “use it or lose it” emerges from such studies and endorses the concept that engagement of mental functions is protective against Alzheimer’s disease or rather can delay its onset.

However, the best studies in these categories assess what an individual has done throughout life, usually over decades. There are fewer conclusions to be drawn about intervention studies, where brain fitness programs are introduced to those at risk for Alzheimer’s disease and rates of development of Alzheimer’s disease measured. The reason is there are very few studies in this category. In particular, many programs claiming benefit in reduction of risk for Alzheimer’s have never been tested in intervention studies. What we do know is that a variety of interventions in normal, elderly adults can improve their memory and other mental faculties. These benefits are usually restricted to the specific faculty being trained and the idea of a crossover into other cognitive areas is hotly disputed.

There remains a great lack of clarity about exactly which type of brain use and the length of time required to engage such activities, is needed to reduce risk for Alzheimer’s disease. Many more studies are needed in this regard, including very long term ones looking at chronic use of brain fitness programs in those at risk for Alzheimer’s disease

Beta Amyloid Alzheimer's Michael  Mullan

Beta Amyloid Alzheimer’s Disease Dr. Michael Mullan

, with examination of the subsequent rates of dementia. Until that time many claims of prevention of Alzheimer’s by certain programs are unproven and may well be misleading, or at best, wishful thinking.

By Dr. Michael Mullan

Roskamp Institute

 

RI-Button-4-animated

  1. Dr. Michael Mullan Article Published in Herald Tribune: Dr. Michael Mullan: Volunteer to help fight Alzheimer’s Comments Off
  2. Donation Campaign – 36 hour giving challenge campaign Comments Off
  3. Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide. Comments Off
  4. Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer’s disease. Comments Off
  5. Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Bachmeier C, Mullan M, Paris D. Comments Off
  6. Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease. Comments Off
  7. Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Comments Off
  8. Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine. Comments Off
  9. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Comments Off
  10. Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid. Comments Off
  11. Flavonoids lower Alzheimer’s Aβ production via an NFκB dependent mechanism. Comments Off
  12. Roskamp Institute in Sarasota, Florida, have shown that an anatabine compound supplied by Rock Creek has beneficial effects on memory and learning in animal models of Alzheimer’s Disease. Michael Mullan, MD, Ph.D., CEO of the Roskamp Institute and his colleague, Dr. Daniel Paris, published these findings in October, 2011 in the European Journal of Pharmacology Comments Off
  13. Mike Mullan Alzheimer Researcher Comments on: Nicotine May Help Combat Memory Loss study by Dr. Newhouse Comments Off
  14. Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model. Comments Off
  15. Anatabine lowers Alzheimer’s Aβ production in vitro and in vivo Comments Off
  16. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Comments Off
  17. Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons. Comments Off
  18. Proteomic CNS profile of delayed cognitive impairment in mice exposed to gulf war agents. Comments Off
  19. Institute targets in on Alzheimer’s Comments Off
  20. Sarasota’s Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes Comments Off
  21. The Roskamp Institute Comments Off
  22. Roskamp Institute on Gulf War Illness Comments Off
  23. The Roskamp Institute Battles Drug Abuse Comments Off
  24. The Traumatic Brain Injury Program at the Roskamp Institute Comments Off
  25. Roskamp Institute finds one of the genetic causes for Tourettes syndrome Comments Off
  26. Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson Comments Off
  27. Dr. Mullan’s Alzheimer Research Offers Invaluable Insights On The Disease Comments Off
  28. Dr. Mullan’s Alzheimer Research Identified Various Genetic Variations Comments Off
  29. Family History of Alzheimer’s disease – what does it mean? Comments Off
  30. ß-amyloid exchage in the blood-brain barrier Comments Off
  31. Why work with Alzheimer’s disease patients? Comments Off
  32. Alzheimer’s disease drug developed at Roskamp Institute approved for key clinical trial funding in Europe Comments Off
  33. Roskamp institute studies may lead to better diagnosis Comments Off
  34. Research Highlights The Direct Causes Related To The Disease Comments Off
  35. Dr. Mullan’s Alzheimer Research Involved Studying Brain Proteins Comments Off
  36. Roskamp Institute researchers show that some antibodies but, not others may be helpful in removing the Alzheimer amyloid from the brain of Alzheimer’s sufferers. Comments Off
  37. Mullan Alzheimer Research Institute Roskamp Institute aids high school students in genetic research Comments Off
  38. The Roskamp Institute investigates the role of anatabine in lowering Alzheimer’s Abeta levels. Comments Off
  39. Alzheimer Research Institute Headed By Dr. Michael Mullan Featured in the Sarasota Herald Tribune : Roskamp Institute research could help veterans Comments Off
  40. Dr. Mullan Alzheimer Presentation at Pines of Sarasota Comments Off
  41. Roskamp Institute Celebrated Veterans Day with a seminar by Alzheimer Researcher Dr. Michael Mullan Comments Off
  42. Alzheimer Expert Dr. Mullan’s comments on CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF) Comments Off
  43. Alzheimer Researcher Dr. Michael Mullans Note on Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide. Comments Off
  44. Effect of NSAIDS on cognitive ability of Alzheimer’s Patient — Comment by Alzheimer Researcher Mullan Comments Off
  45. Dr. Mullan’s Alzheimer Research Notes on NSAIDS and their effect on Alzheimers disease Comments Off
  46. Roskamp Institute Gulf War Illness research program Comments Off
  47. Event: Journal Club “Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade” Comments Off
  48. Event: Journal Club “The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease” Comments Off
  49. News:Nomination for Business/Education Partnership Award through the School District of Manatee County’s ePIE program Comments Off
  50. News:Roskamp Institute was recognized by the South East High School Technical Student association for partnering will the in a diabetes project Comments Off
  51. News: FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS Comments Off
  52. Event: Journal Club “NF-jB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis” Comments Off
  53. News Comments Off
  54. APOLIPOPROTEIN E GENOTYPE AND OXIDATIVE STRESS RESPONSE TO TRAUMATIC BRAIN INJURY Comments Off
  55. Event Journal Club:Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice Comments Off
  56. Event: Journal Club Comments Off
  57. Announcement Comments Off
  58. News:Dr Crawford will be speaking at 2nd Annual Girls S.T.E.M. Summit Comments Off
  59. Alzheimer’s beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2 Comments Off
  60. Tech Tips, #2: Making a homemade frit for fused silica columns Comments Off
  61. Do You Or Someone You Care For Suffer From Alzheimer’s Disease? Comments Off
  62. Reduction of b-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease Comments Off
  63. NEWS RELEASE:Investigational Immune Intervention Slows Brain Atrophy in Alzheimer’s Patients Comments Off
  64. Journal Club Comments Off
  65. FREE MEMORY SCREENING-Sarasota FL Comments Off
  66. Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide Comments Off
  67. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer’s disease Comments Off
  68. CD40/CD40L interaction induces Abeta production and increases gamma-secretase activity independently of tumor necrosis factor receptor associated factor (TRAF) signaling. Comments Off
  69. Roskamp Institute Poster Abstract from VA Reasearch Week Comments Off
  70. Handling Unstructured Data in Biological Research and Clinical Trials Comments Off
  71. Tech Tips: Comments Off
  72. Roskamp Institute is participating in VA Research Week Activities Comments Off
  73. Roskamp Institute-LECOM collaboration Comments Off
  74. High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer’s disease patients Comments Off
  75. Journal Club: The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia Comments Off
  76. Alzheimer’s Disease Anti-Inflammatory Prevention Trial Comments Off
  77. Roskamp Institute is at Facebook! Comments Off
  78. Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease Comments Off
  79. Characteristics of thein VitroVasoactivity of β-Amyloid Peptides Comments Off
  80. Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease Comments Off
  81. Cross Validation of the Montreal Cognitive Assessment in Community Dwelling Older Adults Residing in the Southeastern US Comments Off
  82. Volunteers for early detection of cognitive decline in older adults Comments Off
  83. Roskamp Institute hosted a town hall meeting for the Alzheimer’s Association. Comments Off
  84. Roskamp Institute Scientist Awarded a grant from the Alzheimers Association to investigate a novel therapeutic agent for the treatment of Alzheimer’s Disease. Comments Off
  85. Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer’s Disease. Comments Off
  86. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program Comments Off
  87. Southeast High School’s Roskamp Institute project placed first in Florida and fifth in National Technology Students Association finals Comments Off
  88. Local Researchers at Roskamp Institute to Test Investigational Gammaglobulin Treatment for Alzheimer’s Disease Comments Off
  89. World Alzheimer’s Day: Leaders Call for Early Diagnosis and Aggressive Research Comments Off
  90. Dementia in Older Women Comments Off
  91. Alzheimer’s and Blood Pressure Comments Off
  92. What do the names of Barack Obama, Hillary Clinton, and John McCain have to do with Alzheimer’s disease? Comments Off
  93. Double Amyloid Causes Memory Loss Comments Off
  94. First Critical Clinical Tests of the Amyloid Theory of Alzheimer’s Disease Comments Off
  95. Elan Vaccine and Alzheimer’s Disease Drug development Comments Off
  96. Alzheimer’s Disease Drug development Comments Off
  97. Clinical research for Alzheimer’s Disease at the Roskamp Institute Comments Off
  98. DRUG ADDICTION RESEARCH AT THE ROSKAMP INSTITUTE Comments Off
  99. Traumatic Brain Injury in the War Zone Comments Off
  100. Research On Traumatic Brain Injury At The Roskamp Institute Comments Off
  101. ABeta as Antiangiogenic drug Comments Off
  102. Roskamp Institute examines the cellular responses to biological warfare agents Comments Off
  103. Clinical Trials for Alzheimer’s Disease at the Roskamp Institute Comments Off
  104. Press release for James & Esther King Biomedical Research Program grant Comments Off
  105. Genetic manipulation of CD40L reduces Tau phosphorylation Comments Off
  106. The granulocyte macrophage-colony stimulating factor (GM-CSF) regulates amyloid production Comments Off
  107. Potent antiangiogenic motif in amyloid beta Comments Off
  108. CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF) Comments Off
  109. Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide Comments Off
  110. Effect of NSAIDS on cognitive ability of Alzheimer’s Patients Comments Off
  111. NSAIDS and their effect on Alzheimers disease Comments Off
  112. Roskamp Institute is Part of a Great Technology Cluster Comments Off
  113. Roskamp Institute Receives Lung Cancer Research Grant Comments Off
  114. Roskamp Institute Recognized for Its Beautification Efforts Comments Off
  115. Roskamp Institute Helps Florida’s Economy Comments Off
  116. Roskamp Institute Supports Moves for Greater State Funding of Biotech Research Comments Off
  117. Roskamp Institute Looking for Alzheimer’s Clinical Trial Participants Comments Off
  118. The Roskamp Institute Plans Alzheimer’s Treatment Trial Comments Off
  119. Roskamp’s Fiona Crawford to Participate in Panel Discussion Comments Off
  120. Roskamp Institute Will Host Neuroscience Doctorate Research Program Comments Off
  121. Roskamp Institute Alzheimer’s Research Validated by Independent Japanese Study Comments Off
  122. Roskamp Institute Receives Award of Appreciation Comments Off
  123. Roskamp Institute Studying Potential Usefulness of Beta-amyloid in Treating Alzheimer’s Comments Off
  124. Nilvadipine an anti-hypertensive drug, as a potential treatment for Alzheimer’s disease Comments Off
  125. Anti-hypertension Drugs and Alzheimers Comments Off
  126. Roskamp Institute’s Fiona Crawford to Moderate at Power of Women Series Comments Off
  127. Conscientious people are less prone to Alzheimer’s Comments Off
  128. The Traumatic Brain Injury Program at the Roskamp Institute Comments Off
  129. Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson Comments Off
  130. Senator Nelson Visit Roskamp Institute Comments Off
  131. Roskamp Institute Aims to Help Injured Soldiers Comments Off
  132. British Experts Question Need for Baby Scans Comments Off
  133. Chromosomes Shed New Light on Down Syndrome Comments Off
  134. Down Syndrome Patient Learning New Skills Comments Off
  135. Novartis Required to Correct Advertising Comments Off
  136. Tracking Wandering Alzheimer’s Sufferers Comments Off
  137. Alzheimer’s Caregiver Training Comments Off
  138. Attending College with Intellectual Disabilities Comments Off
  139. National Down Syndrome Society Comments Off
  140. Alzheimer’s Widow to Serve as British Government Adviser Comments Off
  141. Alzheimer’s Disease Disscusion Forum Comments Off
  142. The Roskamp Institute Is Good for Manatee County, Florida Comments Off
  143. Roskamp Institute Obesity and Diabetes Study Official Release Comments Off
  144. Roskamp Institute Study Examines Obesity Comments Off
  145. Clinical Trial Information Comments Off
  146. Sarkozy Vows to Defeat Alzheimer’s Comments Off
  147. Study: Spice can help Alzheimer’s Patients Comments Off
  148. Want a job in science research? Comments Off
  149. Roskamp Institute Tries to Improve Life of Alzheimer’s Suffers Comments Off
  150. Neuropsychology Comments Off
  151. Study: Alzheimer’s Cases May Quadruple by 2050 Comments Off
  152. Alzheimer’s Support Groups Comments Off
  153. Roskamp Celebrated 2006 World Alzheimer’s Day with Clinical Trial Lauch Comments Off
  154. Good News for Alzheimer’s Drug Comments Off
  155. Roskamp Institute Announces New Treatment Comments Off
  156. Roskamp Institute Media Coverage Comments Off
  157. The Roskamp Institute is Participating in a New Phase III MS Study Comments Off
  158. Michael Mullan Featured in Another Story Comments Off
  159. Roskamp’s Michael Mullan Interviewed by St. Petersburg Times Comments Off
  160. Sarasota’s Roskamp Institute Announces Participation in Multiple Sclerosis Study Comments Off
  161. Roskamp Institute recruiting for clinical trials Comments Off
  162. Roskamp Institute Announces New Class Of Drugs That Can Impact Alzheimer’s Disease Comments Off